Session Information

  • WCLC 2022

    2022 World Conference on Lung Cancer

    Conference Program for 2022 the World Conference on Lung Cancer

    Presentation Date(s):  
    • August 6 - 9, 2022
    • Total Presentations: 2137

    All times listed are in Vienna, Austria Time, CEST (UTC+2:00)

    PL - Plenary
    IBS - Interactive Breakfast Session (in-person attendees only)
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    P - Posters
    EP - ePosters
    WS - Workshops
    LA – Lectureship Awards
    IS - Industry Symposium

Filter Results:

Show Only CME Accredited Sessions

  • +

    WS08 - Joint IASLC-CSCO-CAALC Session: Liquid Biopsy in Oncogene Driven NSCLC (On-demand)

    • 21:00 - 23:59
    • 8/06/2022
    • Location: On-Demand
    • Not for CME Credit
    • Type: Workshop
    • Track: N/A
    • +

      Session Moderator

      21:00 - 21:00  |  Presenter: Yi-Long Wu

      • Abstract

      Loading...

    • +

      Session Moderator

      21:00 - 21:00  |  Presenter: Chunxue Bai

      • Abstract

      Loading...

    • +

      Session Moderator

      21:00 - 21:00  |  Presenter: Caicun Zhou

      • Abstract

      Loading...

    • +

      Session Moderator

      21:00 - 21:00  |  Presenter: Karen Kelly

      • Abstract

      Loading...

    • +

      WS08.01 - Session Introduction

      21:00 - 21:02  |  Presenter: Yi-Long Wu

      • Abstract

      Loading...

    • +

      WS08.02 - Session Introduction

      21:02 - 21:04  |  Presenter: Chunxue Bai

      • Abstract

      Loading...

    • +

      WS08.03 - Session Introduction

      21:04 - 21:07  |  Presenter: Caicun Zhou

      • Abstract

      Loading...

    • +

      WS08.04 - Session Introduction

      21:07 - 21:10  |  Presenter: Karen Kelly

      • Abstract

      Loading...

    • +

      WS08.05 - Minimal Residual Disease (MRD) Negative: Potential for Cure in Resected Oncogene Driven NSCLC? Chinese Perspective

      21:10 - 21:30  |  Presenter: Jia-Tao Zhang

      • Abstract

      Loading...

    • +

      WS08.06 - Could MRD Change Our Clinical Practice? North American Perspective

      21:30 - 21:50  |  Presenter: Aadel Chaudhuri

      • Abstract

      Loading...

    • +

      WS08.07 - How to Use Liquid Biopsy to Monitor Treatment Efficacy for Advanced Driven NSCLC

      21:50 - 22:10  |  Presenter: Jie Hu

      • Abstract

      Loading...

    • +

      WS08.08 - Liquid Biopsy for Advanced Oncogene Driven NSCLC. European Perspective

      22:10 - 22:30  |  Presenter: Martin Filipits

      • Abstract

      Loading...

    • +

      WS08.09 - Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer

      22:30 - 22:40  |  Presenter: Si-Yang Maggie Liu

      • Abstract

      Loading...

    • +

      WS08.10 - Toripalimab in Combination with CIK Cells in Patients with Advanced NSCLC: An Exploratory Study

      22:40 - 22:50  |  Presenter: Xuxinyi Ling

      • Abstract

      Loading...

    • +

      WS08.11 - Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis

      22:50 - 23:00  |  Presenter: Yun Fan

      • Abstract

      This abstract is currently under embargo and will be released during the conference.

    • +

      WS08.12 - Discussant for Oral Abstracts

      23:00 - 23:20  |  Presenter: Sai-Hong Ignatius Ou

      • Abstract

      Loading...

    • +

      WS08.13 - Activity of aPD1-MSLN-CART Cells Against Metastatic Lung Cancer in a Phase 1 Trial

      23:20 - 23:21  |  Presenter: Xiaorong Dong

      • Abstract

      Loading...

    • +

      WS08.14 - Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-Negative NSCLC

      23:21 - 23:22  |  Presenter: Lin Wu

      • Abstract

      Loading...

    • +

      WS08.15 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC

      23:22 - 23:23  |  Presenter: Jun Zhao

      • Abstract

      Loading...

    • +

      WS08.16 - The Increase of Blood Intratumor Heterogeneity is Associated with Unfavorable Outcomes of ICIs Plus Chemotherapy in NSCLC

      23:23 - 23:24  |  Presenter: Juan Zhou

      • Abstract

      Loading...

    • +

      WS08.17 - Utilization of Tumor Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer

      23:24 - 23:25  |  Presenter: Wenbin Li

      • Abstract

      Loading...

    • +

      WS08.18 - Discussant for Poster 1 - 5

      23:25 - 23:40  |  Presenter: Xiaorong Dong

      • Abstract

      Loading...

    • +

      WS08.19 - Phase Il Trial of Neoadjuvant Tislelizumab with Chemotherapy for Resectable Stage IIB-III Non-small Cell Lung Cancer

      23:40 - 23:41  |  Presenter: Yao-Bin Lin

      • Abstract

      Loading...

    • +

      WS08.20 - Comprehensive Analysis of a Dendritic Cell Marker Genes Signature to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma

      23:41 - 23:42  |  Presenter: Yuan Li

      • Abstract

      Loading...

    • +

      WS08.21 - Immune Evolution of Metastases & Underlying Molecular Mechanisms in Non-small Cell Lung Cancer

      23:42 - 23:43  |  Presenter: Wen-Fang Tang

      • Abstract

      Loading...

    • +

      WS08.22 - Neoadjuvant Toripalimab Combination in Patients with Stage IIB-IIIB NSCLC: A Single-arm, Phase 2 Trial (Renaissance Study)

      23:43 - 23:44  |  Presenter: Shi Yan

      • Abstract

      Loading...

    • +

      WS08.23 - Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer with Four Structure-Based EGFR-Mutation Subgroups

      23:44 - 23:45  |  Presenter: Shun Lu

      • Abstract

      Loading...

    • +

      WS08.24 - Discussant for Poster 6 - 10

      23:35 - 23:50  |  Presenter: Ming Fang Zhao

      • Abstract

      Loading...

  • +

    MA02 - Molecular Underpinnings of Lung Cancer Histological Differentiation and Targeted Therapeutics

    • 10:45 - 11:45
    • 8/07/2022
    • Location: Hall C8
    • Not for CME Credit
    • Type: Mini Oral
    • Track: Tumor Biology and Biomarkers
    • +

      MA02.05 - Dynamic Mutation Profiles of SCLC Transformation in NSCLC Patients Harboring Concurrent EGFR/TP53/RB1 Mutations

      10:57 - 11:02  |  Presenter: Jie Huang

      • Abstract

      Loading...

  • +

    OA02 - From Locally Advanced to Unresectable NSCLC: Improvement of Multimodality Treatment

    • 12:00 - 13:00
    • 8/07/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Oral
    • Track: Locally Advanced Non-small Cell Lung Cancer
    • +

      OA02.05 - Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study

      12:22 - 12:32  |  Presenter: Yi-Long Wu

      • Abstract

      Loading...

  • +

    OA03 - Molecular Targeted Treatments

    • 14:30 - 15:40
    • 8/07/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Oral
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      OA03.05 - Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C

      14:52 - 15:02  |  Presenter: Michael Thomas

      • Abstract

      Loading...

  • +

    EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
    • +

      EP08.01-070 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC

      Presenter: Jun Zhao

      • Abstract

      Loading...

    • +

      EP08.01-071 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC

      Presenter: Jun Zhao

      • Abstract

      Loading...

    • +

      EP08.01-085 - Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer

      Presenter: Si-Yang Maggie Liu

      • Abstract

      Loading...

  • +

    EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      EP08.02-049 - A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, In Patients With Advanced Solid Tumors With HER2 Aberrations

      Presenter: Frans Opdam

      • Abstract

      Loading...

    • +

      EP08.02-063 - SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC

      Presenter: Qing Zhou

      • Abstract

      Loading...

    • +

      EP08.02-064 - ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)

      Presenter: Qing Zhou

      • Abstract

      Loading...

    • +

      EP08.02-108 - Osimertinib Long-Term Tolerability in Patients with EGFRm NSCLC Enrolled in the AURA Program or FLAURA Study

      Presenter: Marina Chiara Garassino

      • Abstract

      Loading...

  • +

    EP10.01 - Palliative and Supportive Care

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Palliative and Supportive Care
    • +

      EP10.01-010 - Real-world Study of the Incidence and Risk Factors of Venous Thromboembolism in Chinese Lung Cancer (RIVAL)

      Presenter: ZHEN WANG

      • Abstract

      Loading...

  • +

    EP16.01 - Tumor Biology and Biomarkers - Immune Biology & Immunotherapy

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Tumor Biology and Biomarkers - Immune Biology & Immunotherapy
    • +

      EP16.01-025 - Immune Evolution of Metastases & Underlying Molecular Mechanisms in Non-small Cell Lung Cancer

      Presenter: Wen-Fang Tang

      • Abstract

      Loading...

  • +

    EP16.02 - Tumor Biology and Biomarkers - Minimally Invasive Biomarkers

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Tumor Biology and Biomarkers - Minimally Invasive Biomarkers
    • +

      EP16.02-024 - Plasma ctDNA Organ-Specific Genomic Patterns and Origination Analysis in Advanced Non-Small Cell Lung Cancer

      Presenter: Rui Fu

      • Abstract

      Loading...

  • +

    OA15 - Patient Selection in Advanced NSCLC Immunotherapy

    • 14:30 - 15:30
    • 8/09/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Oral
    • Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
    • +

      OA15.06 - Pooled Analysis of Outcomes With Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer

      15:02 - 15:12  |  Presenter: Delvys Rodriguez-Abreu

      • Abstract

      Loading...